TAS1440 benzoate

Overview

TAS1440 benzoate is an orally active LSD1/KDM1A inhibitor with a human IC 50 of 4.8 nM. TAS1440 benzoate non-covalently binds to the histone H3 -binding pocket of LSD1, inhibiting demethylase activity and disrupting repressive complexes with INSM1 and SMAD2 . TAS1440 benzoate activates tumor-suppressive TGF-β and NOTCH signaling pathways via transcriptional reprogramming. TAS1440 benzoate can be used for the research of small cell lung cancer , specifically the SCLC-A subtype.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Demethylase | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Notch

Product Information

• Catalog No.: HY-183067A
• CAS No.: 2642224-15-3
• Molecular Formula: C35H33F2N3O4
• Molecular Weight: 597.65
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source